A family-run investment and commercialization vehicle based in the Asia Pacific region invests in early-stage life science and technologies. The group is flexible in terms of deal structure with past investments ranging from minority commitments in a funding round to in-licensing entire therapeutic programs.
The firm specializes in therapeutic opportunities and has a particular focus on rare diseases. The group is most interested in indications where the pathophysiology is well-understood, the developmental pathway is straight-forward, and there is a clear unmet medical need. Opportunities that are de-risked in some way, such as reformulation or repurposing plays, are also attractive to the firm.
The firm has a strong preference for experienced management teams with proven tracks records of driving value.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply